Tag: targeted therapy
-
Encorafenib/Cetuximab Plus FOLFIRI: A Potential Frontline SOC for BRAF V600E+ mCRC
Overview: A New frontline strategy for BRAF V600E–mutant mCRC Metastatic colorectal cancer (mCRC) with the BRAF V600E mutation has historically challenged clinicians due to its aggressive behavior and poorer prognosis. Recent evidence suggests that a triplet combination—encorafenib (a BRAF inhibitor) plus cetuximab (an EGFR inhibitor) and FOLFIRI (folinic acid, 5-fluorouracil, and irinotecan)—may offer meaningful improvements…
-
Australian Researchers Unveil Targeted Therapy for Rare Blood Cancer Myelofibrosis
Breakthrough in Myelofibrosis Treatment In a promising development for patients with myelofibrosis, a rare and serious blood cancer, Australian researchers have advanced a new targeted therapeutic approach. The study, conducted by a team from leading medical centers, focuses on a specific molecular pathway that drives the disease’s progression. By honing in on this pathway, the…
-
Australian researchers pioneer targeted therapy for rare blood cancer myelofibrosis
Australian researchers unveil a new targeted therapy for myelofibrosis New Delhi, Jan 12 — A team of Australian researchers has announced a promising targeted therapeutic approach that could reshape how myelofibrosis is treated. Myelofibrosis is a rare and serious blood cancer that disrupts the bone marrow’s ability to produce healthy blood cells, leading to fatigue,…
-
Australian Breakthrough: Targeted Therapy for Myelofibrosis
New Hope for a Rare Blood Cancer A team of Australian researchers has announced a targeted therapeutic approach that could transform treatment for myelofibrosis, a rare and serious blood cancer characterized by abnormal blood cell production and scarring of the marrow. While myelofibrosis remains a challenging disease with limited treatment options for some patients, the…
-
Continued Zenocutuzumab Shows Benefit Beyond Progression in NRG1+ Pancreatic Cancer and Cholangiocarcinoma (eNRGy)
New Signals of Benefit for Zenocutuzumab Beyond Progression New data from the eNRGy trial (NCT02912949) offer encouraging signals that continuing zenocutuzumab after progression may provide clinical benefits for patients with NRG1+ pancreatic cancer and cholangiocarcinoma. The post hoc analysis presented at ASCO GI highlights how a targeted therapy approach can extend potential options for a…
-
Continued Zenocutuzumab Beyond Progression Shows Benefit in NRG1+ Pancreatic Cancer and Cholangiocarcinoma: eNRGy Trial Results at ASCO GI
New Insights from ASCO GI: Zenocutuzumab Beyond Progression New results from the eNRGy trial highlight a potential new path for patients with NRG1+ pancreatic cancer and cholangiocarcinoma. In a post hoc analysis presented at ASCO GI, researchers evaluated the effects of continuing zenocutuzumab treatment beyond radiographic progression. The findings suggest that patients who stay on…
-
The Dual Role of SLC7A11 in Colorectal Cancer Ferroptosis: From Molecules to Therapies
Understanding Ferroptosis and SLC7A11 Ferroptosis is a regulated form of cell death driven by iron-dependent lipid peroxidation. In colorectal cancer (CRC), ferroptosis represents a promising avenue to overcome resistance to conventional therapies. Central to this process is SLC7A11, a component of the cystine/glutamate antiporter system Xc–, which imports cystine into cells in exchange for glutamate.…
-
Advances in Cu-Cy Nps@ZIF-8@HA-Mediated Photodynamic Therapy for Cutaneous Squamous Cell Carcinoma
Overview: Targeted Photodynamic Therapy for Cutaneous SCC Cutaneous squamous cell carcinoma (cSCC) is a rising global health concern, representing a significant portion of skin cancer cases. Traditional treatments—surgery, radiation, and conventional photodynamic therapy (PDT)—often face limitations such as incomplete tumor clearance and collateral damage to surrounding healthy tissue. Recent research has turned to advanced nanomedicine…
-
Cu-Cy Nps@ZIF-8@HA-Mediated Photodynamic Therapy for Cutaneous Squamous Cell Carcinoma: Advances and Promise
Overview: A New Frontier in Photodynamic Therapy for Skin Cancer Cutaneous squamous cell carcinoma (cSCC) is a common and increasingly prevalent skin cancer. Traditional treatments include surgical excision, Mohs surgery, and radiotherapy, but these approaches can be invasive or unsuitable for certain patients. Emerging photodynamic therapy (PDT) strategies offer targeted, minimally invasive options that minimize…
-
Cu-Cy Nps@ZIF-8@HA-Mediated Photodynamic Therapy for Cutaneous Squamous Cell Carcinoma: A Promising Approach
Introduction to Cutaneous Squamous Cell Carcinoma and Photodynamic Therapy Cutaneous squamous cell carcinoma (CSCC) is one of the most common skin cancers, representing a significant portion of non-mmelanoma skin cancers worldwide. While many cases are treatable with surgery and radiation, novel therapies are needed for advanced or drug-resistant CSCC. Photodynamic therapy (PDT) has emerged as…